New cell therapy tested for patients out of treatment options
NCT ID NCT07376642
Summary
This early-stage study is testing a new cell therapy called IMV101 in adults whose B-cell non-Hodgkin lymphoma has come back or hasn't responded to at least two prior treatments. The main goals are to find a safe dose and see if the therapy shows early signs of fighting the cancer. Researchers will track side effects and how the cancer responds in about 30 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Boren Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100070, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cancer Hospital Chinese Academy of Medical Sciences
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhengzhou Yihe Hospital
RECRUITINGZhengzhou, Henan, 450047, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.